Mirtazapine: Other indications

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 17, 1999, Pages 36-40

  Falkai, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DYSPHORIA; HUMAN; MENTAL DISEASE; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MENOPAUSE; MIANSERIN; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 0032843329     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;31:8-19
2. Deakin JFW. The role of serotonin in depression and anxiety. Eur Psychiatry 1998;13(suppl 2):57S-63S
3. Davis JM, Giakas WJ. Mirtazapine: the first million patients. In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacolog) [CD-ROM]; Dec. 14-18, 1998; Las Croabas, Puerto Rico
4. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses on pooled data. Int Clin Psychopharmacol 1995;10:23-35
5. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10:39-47
6. Davidson JRT. The long-term treatment of panic disorder. J Clin Psychiatry 1998;59(suppl 8):17-21
7. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 1998;59(suppl 8):11-14
8. Nutt DJ. Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 1998;59:24-28
9. Zohar J, Sasson Y, Amital D, et al. Current diagnostic issues and epidemiological insights in PTSD. CNS Spectrums, Int J Neuropsych Med 1998;3(suppl 2):11-14
10. Conner KM, Davidson JRT. The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums, Int J Neuropsych Med 1998;3(suppl 2):42-51
11. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990;47: 259-266
12. Reist C, Kauffman CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989;146: 513-516
13. Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol 1997;12: 231-237
14. McDougle CJ, Southwick SM, Charney DS, et al. An open trial of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1991;11:325-327
15. Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat vets with PTSD. J Trauma Stress 1992;97-101
16. Nagy LM, Morgan III CA, Southwick SM, et al. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol 1993; 13:107-113
17. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;55:517-522
18. De Boer M, Op den Velde W, Flager RJR, et al. Fluvoxamine treatment for combat-related posttraumatic stress disorder. Psychother Psychosoin 1991; 57:158-163
19. Marmar CR, Schoenfeld F, Weiss DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 1996;57(suppl 8):66-70
20. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress 1996;9: 865-871
21. Kline NA, Dow BM, Brown SA, et al. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder [letter]. Am J Psychiatry 1994;151:621
22. Davidson JRT, Weisler RH, Malik ML, et al. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol 1998;13: 111-113
23. Conner KM, Davidson JRT, Weisler RH. A pilot study of mirtazapine in posttraumatic stress disorder In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology; Dec. 14-18, 1998; Las Croabas, Puerto Rico
24. Goodnick PJ, Puig A, DeVane CL. Mirtazapine in combined major depression and generalized anxiety disorder [poster]. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec. 8-12, 1997; Waikoloa, Hawaii:145
25. Frances A. Recurrent brief depression, dysthymia and melancholia. Int Clin Psychopharmacol 1993;7:197-200
26. Montgomery SA, Montgomery D, McAuley R, et al. Maintenance therapy in repeated suicidal behaviour: a placebo-controlled trial. In: Proceedings of the 10th International Congress for Suicide Prevention and Crisis Intervention; 1979; Ottawa, Canada:227-229
27. Montgomery SA, Montgomery D, Evans R. Pharmacological differences between brief and major depressions. Eur Neuropsychopharmacol 1993;3(suppl 3):214-215
28. Stamenkovic M, Pezawas L, de Zwaan M. Mirtazapine in recurrent brief depression. Int Clin Psychopharmacol 1998;13:39-40
29. Dunner DL, Hendrickson HE, Budech C, et al. Mirtazapine: treatment of dysthymic disorder. In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology [CD-ROM]; Dec. 14-18, 1998; Las Croabas, Puerto Rico
30. Isaac MT, Tome MB. Mirtazapine in peri-menopausal depression: an open label study. In: Scientific Abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology [CD-ROM]; Dec. 14-18, 1998; Las Croabas, Puerto Rico